[Intraepithelial neoplasia of Barrett's esophagus: prognosis of potential malignancy].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Werner M;Werner M; Lassmann S
  • Source:
    Der Pathologe [Pathologe] 2011 Nov; Vol. 32 Suppl 2, pp. 197-201.
  • Publication Type:
    Journal Article; Review
  • Language:
    German
  • Additional Information
    • Transliterated Title:
      Intraepitheliale Neoplasie des Barrett-Ösophagus: Vorhersage des malignen Potenzials.
    • Source:
      Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8006541 Publication Model: Print Cited Medium: Internet ISSN: 1432-1963 (Electronic) Linking ISSN: 01728113 NLM ISO Abbreviation: Pathologe Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin, New York, Springer-Verlag.
    • Subject Terms:
      Adenocarcinoma/*pathology ; Barrett Esophagus/*pathology ; Carcinoma in Situ/*pathology ; Cell Transformation, Neoplastic/*pathology ; Esophageal Neoplasms/*pathology; Adenocarcinoma/genetics ; Aneuploidy ; Apoptosis/genetics ; Barrett Esophagus/genetics ; Biopsy ; Carcinoma in Situ/genetics ; Cell Proliferation ; Cell Transformation, Neoplastic/genetics ; Cyclin D1/genetics ; Esophageal Neoplasms/genetics ; Esophagus/pathology ; Gene Expression Regulation, Neoplastic/genetics ; Genetic Markers/genetics ; Immunohistochemistry ; Loss of Heterozygosity/genetics ; Prognosis ; Tetraploidy ; Tumor Suppressor Protein p53/genetics ; Ubiquitin-Protein Ligases/genetics
    • Abstract:
      Adenocarcinomas of the distal esophagus mainly develop from intestinal metaplasia (Barrett's esophagus) through intermediate steps of low-grade and high-grade intraepithelial neoplasia. Histopathological examination of endoscopic biopsies constitutes the gold standard for estimating the cancer risk of a patient with Barrett's esophagus. Several prospective biomarker phase IV studies have demonstrated the predictive value of e.g. allelic loss of TP53, tetraploidy and aneuploidy as well as cyclin D1 expression. Among the relevant biomarkers from retrospective phase III studies are polysomy and specific DNA gains and losses, markers of proliferation (Mib-1) and methylation markers. As there are conflicting results in the literature and these analyses are costly, their use in routine patient care cannot yet be recommended. However, immunostaining for several markers may assist in the classification of intraepithelial neoplasia in individual difficult cases.
    • References:
      Cancer Res. 2004 Oct 15;64(20):7629-33. (PMID: 15492292)
      Am J Surg Pathol. 2009 Jun;33(6):886-93. (PMID: 19194279)
      J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21. (PMID: 10944553)
      Z Gastroenterol. 2005 Feb;43(2):163-4. (PMID: 15700206)
      Cancer. 1995 Jan 15;75(2):423-9. (PMID: 7812911)
      Mod Pathol. 2009 Dec;22(12):1612-21. (PMID: 19734842)
      Mod Pathol. 2010 Jan;23(1):1-11. (PMID: 19838164)
      J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61. (PMID: 11459866)
      Gastroenterology. 2005 Dec;129(6):1825-31. (PMID: 16344051)
      Arch Pathol Lab Med. 2010 Oct;134(10):1479-84. (PMID: 20923304)
      Clin Gastroenterol Hepatol. 2010 Mar;8(3):235-44; quiz e32. (PMID: 19850156)
      Am J Gastroenterol. 1999 Dec;94(12):3413-9. (PMID: 10606296)
      Am J Gastroenterol. 2004 Sep;99(9):1657-66. (PMID: 15330898)
      Hum Pathol. 2008 Aug;39(8):1128-35. (PMID: 18602665)
      Eur J Gastroenterol Hepatol. 2005 Sep;17(9):943-50. (PMID: 16093872)
      Arch Pathol Lab Med. 2010 Nov;134(11):1589-600. (PMID: 21043812)
      Am J Gastroenterol. 2009 Nov;104(11):2673-80. (PMID: 19638963)
      Am J Gastroenterol. 2001 Oct;96(10):2839-48. (PMID: 11693316)
      Int J Cancer. 2004 Dec 10;112(5):747-53. (PMID: 15386389)
      Cancer Res. 2009 May 15;69(10):4112-5. (PMID: 19435894)
      Am J Pathol. 2000 Feb;156(2):555-66. (PMID: 10666385)
      Gastroenterology. 2001 Jun;120(7):1630-9. (PMID: 11375945)
      Am J Clin Pathol. 2008 Nov;130(5):745-53. (PMID: 18854267)
      Am J Surg Pathol. 2006 Apr;30(4):423-35. (PMID: 16625087)
      Gastroenterology. 2001 Jun;120(7):1607-19. (PMID: 11375943)
      Cancer Res. 2004 May 15;64(10):3414-27. (PMID: 15150093)
      Gut. 2006 Oct;55(10):1390-7. (PMID: 16682429)
      Gastroenterology. 2010 Mar;138(3):854-69. (PMID: 20080098)
      Am J Gastroenterol. 2001 Nov;96(11):3071-83. (PMID: 11721752)
    • Accession Number:
      0 (CCND1 protein, human)
      0 (Genetic Markers)
      0 (TP53 protein, human)
      0 (Tumor Suppressor Protein p53)
      136601-57-5 (Cyclin D1)
      EC 2.3.2.27 (MIB1 ligase, human)
      EC 2.3.2.27 (Ubiquitin-Protein Ligases)
    • Publication Date:
      Date Created: 20111029 Date Completed: 20120320 Latest Revision: 20211020
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s00292-011-1493-4
    • Accession Number:
      22033682